Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users

Rhea-AI Summary

Omada Health (Nasdaq: OMDA) will present two ObesityWeek 2025 posters (Nov 4-5, 2025) reporting real-world evidence that Omada’s behavior-change program may improve outcomes for members on or previously on GLP-1 medications for weight loss.

Key findings: 84% persistence at 24 weeks (n=1,124) with greater weight loss for persistent users (12.1% vs 7.4%), a 54% higher odds of persistence per 10 additional weekly engagements, and an average 0.8% weight change at 12 months post-discontinuation (n=95), with 63.2% maintaining or losing weight.

Positive

• 84% GLP-1 persistence at 24 weeks (n=1,124)
• Persistent users lost 12.1% vs 7.4% for early stoppers
• 54% higher odds of persistence per 10 extra weekly engagements
• 0.8% average weight change at 12 months post-GLP-1 discontinuation (n=95)
• 63.2% maintained or continued to lose weight 12 months after stopping GLP-1s

Negative

• Second analysis used a retrospective prescription-claims approach (n=816) rather than a randomized trial
• 12-month post-discontinuation subset small (n=95), limiting sample size for long-term outcome estimates

News Market Reaction

-1.21% 4.2x vol

7 alerts

-1.21% News Effect

-2.3% Trough in 5 hr 27 min

-$16M Valuation Impact

$1.33B Market Cap

4.2x Rel. Volume

On the day this news was published, OMDA declined 1.21%, reflecting a mild negative market reaction. Argus tracked a trough of -2.3% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $16M from the company's valuation, bringing the market cap to $1.33B at that time. Trading volume was very high at 4.2x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Results suggest sustained, long-term impact of Omada’s program on weight loss and longer medication persistence

SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the potential impact of Omada’s behavior change program on members currently or previously on GLP-1 medications for weight loss. Together, these analyses suggest that engagement with Omada may enhance results for members who have been on GLP-1s for weight loss, whether they stay on the medication or not.

Previous clinical studies have suggested that sustained weight loss leads to increased long-term health benefits,¹ including the reduction of comorbidities, and persistence on a GLP-1 is associated with greater weight loss.² Those who stop GLP-1s tend to regain the weight they lost³ on the medication. Omada’s analyses demonstrated the clinical benefit of its wraparound lifestyle program on members at various stages of GLP-1 usage.

Omada Increased GLP-1 Medication Persistence and Weight Loss
The first analysis examined GLP-1 persistence rates of 1,124 Omada members enrolled in Omada’s Enhanced GLP-1 Care Track, which provides tailored support to members on their GLP-1 journey.

The analysis evaluated Omada members at 12 and 24 weeks in the program, examining how factors such as program engagement impacted members’ medication persistence. While real-world evidence has previously found lower GLP-1 persistence rates⁴ compared to clinical trials,⁵ Omada’s analysis demonstrated that support via Omada’s program supported enhanced persistence commensurate with increased engagement; 84% of participants stayed on their medication for 24 weeks and lost more weight than those who stopped earlier (12.1% vs. 7.4%). It also found that for every 10 additional engagements per week in the initial 12 weeks, the odds of medication persistence were 54% higher.

“These findings underscore a critical insight in the evolving landscape of obesity treatment. While GLP-1s are powerful tools, our research demonstrates that lifestyle support programs, like Omada, can enhance their effectiveness,” said Sarah Linke, PhD, MPH, Senior Director, Clinical & Translational Research, Omada Health.

Omada Members Maintained Sustained Weight Lost 12 months Post-Discontinuation
The second analysis looked at weight change during the discontinuation phase of the GLP-1 journey. The team conducted a retrospective analysis using prescription claims to examine 816 total Omada members without type 2 diabetes, evaluating them at 6, 9, and/or 12 months after GLP-1 discontinuation. It found that, at one year post-discontinuation, members (n=95) experienced 0.8% average weight change,⁶ compared to 11-12% weight gain typically seen in clinical trials,⁷ with 63.2% maintaining or continuing to lose weight at 12 months.

“As channels to access GLP-1s increase and healthcare costs rise,⁸ every dollar invested into patient care counts,” said Wei-Li Shao, President, Omada Health. “These analyses demonstrated that engagement with Omada may enhance the effectiveness of GLP-1 therapy across all stages of treatment – helping to optimize outcomes and reduce wasted financial investment.”

These studies were completed as part of the Omada Insights Lab ANSWERS (ANalyzing Success of WEight medication with Real-world evidence and Stats) Initiative, which examines and shares real-world data from Omada’s behavior change weight health programs.

Both posters will be presented at The Obesity Society’s ObesityWeek 2025 in Atlanta on November 4-5, 2025.

Omada Health
Omada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time. Omada care teams implement clinically-validated behavior change protocols for individuals living with diabetes, hypertension, prediabetes, and musculoskeletal issues. With more than a decade of experience and data, and 30 peer-reviewed publications that showcase its clinical and economic results, Omada is designed to help improve health outcomes and contain healthcare costs. Omada’s scope exceeds 2,000 customers, including health plans, health systems, and employers ranging in size from small businesses to Fortune 500s.

The foundation of Omada’s success is a strong, vibrant work culture, which helped earn the company the distinction of becoming an officially certified Great Place to Work^®. An industry leader, Omada was the first virtual provider to join the Institute for Healthcare Improvement’s Leadership Alliance, reflecting the aim to complement primary care providers for the benefit of members, and affirming its guarantee to every partner: Omada works differently.

Great Place to Work^® is the registered trademark of the Great Place to Work Institute and is used under license.

Contacts
Rose Ramseth
press@omadahealth.com

¹ Ryan DH, Yockey SR. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Curr Obes Rep. 2017;6(2):184-194. doi: 10.1007/s13679-017-0262-y

² Gasoyan H, Butsch WS, Schulte R, et al. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity. 2025;33(9):1657-1667. doi:10.1002/oby.24331

³Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945

⁴Gasoyan H, Pfoh ER, Schulte R, et al. Early- and later-stage persistence with antiobesity medications: A retrospective cohort study. Obesity. 2024;32(3):486-493. doi:10.1002/oby.23952

⁵Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183

⁶Chang H, Devaraj SM, Naqvi JB, Napoleone J, Linke S. Weight maintenance is possible after GLP-1s—with the right support. Omada Health. Published September 8, 2025. Accessed October 2025. https://resourcecenter.omadahealth.com/white-papers/weight-maintenance-is-possible-after-glp-1s-with-the-right-support.

⁷Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945

⁸Umland B, Patel S. Employers prepare for the highest health benefit cost increase in 15 years. Mercer. Published September 3, 2025. Accessed October 2025. https://www.mercer.com/en-us/insights/us-health-news/employers-prepare-for-the-highest-health-benefit-cost-increase-in-15-years/

FAQ

What did Omada Health (OMDA) report at ObesityWeek 2025 on Nov 4-5, 2025?

Omada reported two real-world analyses showing increased GLP-1 persistence and sustained weight maintenance after discontinuation when members engaged with Omada’s program.

How much weight did Omada members who stayed on GLP-1s lose by 24 weeks (OMDA)?

Members who remained on medication lost 12.1% body weight by 24 weeks versus 7.4% for those who stopped earlier.

What persistence improvement did Omada find for GLP-1 users in the OMDA data?

Omada found 84% of participants stayed on GLP-1s for 24 weeks and each 10 extra engagements per week raised persistence odds by 54%.

What were the 12-month outcomes after stopping GLP-1s in Omada’s OMDA analysis?

At 12 months post-discontinuation (n=95), members had an average 0.8% weight change and 63.2% maintained or continued to lose weight.

What sample sizes did Omada use in the GLP-1 persistence and discontinuation analyses (OMDA)?

The persistence analysis included 1,124 members; the discontinuation analysis reviewed 816 members overall with 95 assessed at 12 months post-discontinuation.